Aleksandar D. Sekulic MD, PhD

Dr. Aleksandar Sekulic, M.D., Ph.D., focuses his research interests on developing translational approaches for the study of genomics in skin diseases; identifying the genetics and molecular mechanisms of malignant melanoma; discovering the molecular diagnostics of pigmented lesions, and understanding the regulation of epidermal proliferation and differentiation as it relates to human skin disease.

Dr. Sekulic has extensive and active involvement in basic and translational research as well as clinical trials, exemplified by his role as principal investigator on the ERIVANCE trial, leading to the FDA approval of vismodegib, the first hedgehog pathway inhibitor for the treatment of basal cell carcinoma.

Dr. Sekulic has served as a teacher and mentor for numerous residents and students and is a recipient of the Excellence in Teaching Recognition Award from Mayo Medical School. He has given international, national, and regional presentations and has co-authored numerous articles, book chapters, abstracts, and letters, which have been published in numerous peer‐reviewed journals.